CMV and transfusion
Reviewer: Huy Phu Pham, M.D. (see Reviewers page)
Revised: 1 November 2011, last major update October 2011
Copyright: (c) 2007-2011, PathologyOutlines.com, Inc.
● 50%-85% of US population is CMV+; 50% of US donors are CMV seropositive, compared to 93% in Ghana (Ghana Med J 2006;40:99)
● Seroconversion rate is 1% per year
● CMV is almost always latent in immunocompetent adults; CMV virus is latent in leukocytes
● Leukoreduction reduces risk of CMV transmission
● Leukoreduced blood products are generally considered equivalent to CMV negative products
● CMV can cause pneumonitis, hepatitis, retinitis or organ failure in immunocompromised recipients, who should get CMV negative or leukoreduced blood components (Bone Marrow Transplant 2005;36:499, Transfus Med Rev 2005;19:181)
End of Transfusion Medicine > Tranfusion-transmitted disease > CMV and transfusion
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).